Get the Stockscreener App
33.86
3.33%
1.09
After Hours:
33.85
-0.010
-0.03%
Celldex Therapeutics Inc stock is traded at $33.86, with a volume of 725.60K.
It is up +3.33% in the last 24 hours and up +9.01% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$32.77
Open:
$33.13
24h Volume:
725.60K
Relative Volume:
0.72
Market Cap:
$2.66B
Revenue:
$1.55M
Net Income/Loss:
$-258.76M
P/E Ratio:
-8.6925
EPS:
-3.8953
Net Cash Flow:
$-213.66M
1W Performance:
+1.90%
1M Performance:
+9.01%
6M Performance:
+42.69%
1Y Performance:
+66.88%
1-Day Range:
$32.43
$34.20
1-Week Range:
$31.65
$34.20
52-Week Range:
$17.85
$35.79
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
33.86 | 2.57B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Upgrade | Barclays | Underweight → Overweight |
| Mar-23-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-13-25 | Initiated | Barclays | Underweight |
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - Yahoo Finance
MSN Money - MSN
Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapies and 80+ Companies Advancing Next-Generation Biologics and Small Molecules | DelveInsight - Barchart.com
Vanguard Capital Management (NASDAQ: CLDX) reports 3.45M shares; 5.17% stake - Stock Titan
Celldex earnings on deck as barzolvolimab Phase 3 nears readout By Investing.com - Investing.com South Africa
Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com UK
[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan
Celldex (NASDAQ: CLDX) sets 2026 virtual meeting, seeks approval for equity plan - Stock Titan
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics announces public offering of common stock - MSN
Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump - Yahoo Finance
Is Celldex (CLDX) stock a strategic buy | Q4 2025: EPS Misses ViewsCommunity Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Celldex (CLDX) Operational Review | Q4 2025: Earnings UnderperformPrice Target - Cổng thông tin điện tử tỉnh Lào Cai
Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains - simplywall.st
Why Celldex Stock Is Suddenly Sliding Again - TipRanks
Celldex Therapeutics Inc (CLDX) - MSN
Barclays upgrades Celldex Therapeutics (CLDX) - MSN
Celldex (CLDX) Stock VWAP Analysis (-0.49%) 2026-04-20AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24 - marketscreener.com
Barclays upgrades Celldex stock rating on trial enrollment progress By Investing.com - Investing.com Australia
Barclays upgrades Celldex stock rating on trial enrollment progress - Investing.com UK
Celldex (CLDX) Stock: Performance Drivers (Modest Uptick) 2026-04-18Real Trader Network - Cổng thông tin điện tử tỉnh Lào Cai
Celldex Therapeutics stock hits 52-week high at 34.55 USD By Investing.com - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month HighHere's What Happened - MarketBeat
Celldex Therapeutics stock hits 52-week high at 34.55 USD - Investing.com
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - MarketBeat
CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4 - TradingView — Track All Markets
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex will stream April 14 fireside chat from skin disease event - Stock Titan
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):